AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35198412 — intervention group
Group type: EXPERIMENTAL
Intervention: ECA suggests a relevant topic to discuss
Number of subjects: 82
Study 35198412 — intervention group
Group type: COMPARATOR
Intervention: User selects a topic from a set of options
Number of subjects: 82
Study 32471400 — intervention group
Group type: EXPERIMENTAL
Intervention: A Healthy Generation programme (physical activity and healthy meals/fruit twice a week from August to May)
Number of subjects: 157
Study 32471400 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention details provided)
Number of subjects: 157
Study 34702564 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet preservation strategy
Number of subjects: 104
Study 34702564 — intervention group
Group type: COMPARATOR
Intervention: Leaflet resection strategy
Number of subjects: 104
Study 33822086 — intervention group
Group type: EXPERIMENTAL
Intervention: PPAEAT (Perceptions of Preventable Adverse Events Assessment Tool)
Number of subjects: 210
Study 32331079 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasotraline (4-8 mg/d)
Number of subjects: 317
Study 32331079 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasotraline
Number of subjects: 317
Study 32331079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 34859618 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based nomogram for predicting distant metastasis (DM) risk in LMS patients
Number of subjects: 2184
Study 34859618 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based nomogram
Number of subjects: 2184
Study 34859618 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithelioid LMS, older age, giant tumor, multiple organ metastasis, without surgery, and chemotherapy
Number of subjects: 2184
Study 32961617 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg
Number of subjects: 222
Study 32961617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 36050560 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐PLEX100 plus standard of care (SOC)
Number of subjects: 202
Study 36050560 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 202
Study 33648464 — intervention group
Group type: EXPERIMENTAL
Intervention: MiSight contact lenses (CL)
Number of subjects: 74
Study 33648464 — intervention group
Group type: COMPARATOR
Intervention: Single-vision spectacles (control)
Number of subjects: 74
Study 32638017 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentum preservation
Number of subjects: 1050
Study 32638017 — intervention group
Group type: COMPARATOR
Intervention: Omentectomy
Number of subjects: 1050
Study 35304391 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly online ePROM symptom reporting
Number of subjects: 52
Study 35304391 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 52
Study 32583541 — intervention group
Group type: EXPERIMENTAL
Intervention: Blackberry-dill extract combination
Number of subjects: 0
Study 32583541 — intervention group
Group type: EXPERIMENTAL
Intervention: Blackberry extract
Number of subjects: 0
Study 32583541 — intervention group
Group type: EXPERIMENTAL
Intervention: Dill extract
Number of subjects: 0
Study 32583541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34230015 — intervention group
Group type: EXPERIMENTAL
Intervention: CONTRACT intervention involving family-oriented and supervised home-based training, diet, and electrical muscle stimulation for 6 months.
Number of subjects: 50
Study 34230015 — intervention group
Group type: COMPARATOR
Intervention: Standard care as offered by local hospital or community (Control group).
Number of subjects: 50
Study 34814908 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality nursing based on childlike interest
Number of subjects: 62
Study 34814908 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing intervention
Number of subjects: 62
Study 35882814 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation (3 g per packet, 1 packet per day for 2 weeks)
Number of subjects: 17
Study 34333414 — intervention group
Group type: EXPERIMENTAL
Intervention: BoPo posts featuring average-size women
Number of subjects: 167
Study 34333414 — intervention group
Group type: EXPERIMENTAL
Intervention: BoPo posts featuring larger women
Number of subjects: 167
Study 34333414 — intervention group
Group type: COMPARATOR
Intervention: BoPo posts (both conditions)
Number of subjects: 167
Study 34333414 — intervention group
Group type: COMPARATOR
Intervention: Travel/Control
Number of subjects: 167
Study 32107360 — intervention group
Group type: EXPERIMENTAL
Intervention: BCTC
Number of subjects: 32
Study 32107360 — intervention group
Group type: COMPARATOR
Intervention: A‐967079
Number of subjects: 32
Study 32107360 — intervention group
Group type: COMPARATOR
Intervention: Amiloride
Number of subjects: 32
Study 32107360 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all 3 antagonists (BCTC, A‐967079, amiloride)
Number of subjects: 32
Study 35611069 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg twice daily
Number of subjects: 1372
Study 35611069 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 150 mg twice daily
Number of subjects: 1372
Study 35611069 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches 21 mg/day with taper
Number of subjects: 1372
Study 35611069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1372
Study 34056910 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 34056910 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 34056910 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of HF
Number of subjects: 0
Study 34056910 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥66 years
Number of subjects: 0
Study 34056910 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 0
Study 34056910 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight
Number of subjects: 0
Study 32281732 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet soda containing sucralose and acesulfame‐potassium (Ace‐K) consumed three times daily for 8 weeks
Number of subjects: 7
Study 32281732 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet soda containing sucralose and acesulfame‐potassium (Ace‐K)
Number of subjects: 7
Study 35045221 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (20 mg orally once daily) plus Pembrolizumab (200 mg intravenously every 3 weeks)
Number of subjects: 827
Study 35045221 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (doxorubicin at 60 mg/m² every 3 weeks or paclitaxel at 80 mg/m² weekly)
Number of subjects: 827
Study 35045221 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus Pembrolizumab
Number of subjects: 827
Study 35045221 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 827
Study 34108078 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 1.91 μg (ED90)
Number of subjects: 40
Study 34108078 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 2 μg (recommended dosage)
Number of subjects: 40
Study 33032824 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop Electrosurgical Excision Procedure (LEEP)
Number of subjects: 40
Study 33032824 — intervention group
Group type: COMPARATOR
Intervention: Cold Knife Cone Biopsy (CKC)
Number of subjects: 40
Study 33032824 — intervention group
Group type: COMPARATOR
Intervention: CKC
Number of subjects: 40
Study 33032824 — intervention group
Group type: EXPERIMENTAL
Intervention: LEEP
Number of subjects: 40
Study 34516998 — intervention group
Group type: COMPARATOR
Intervention: Education (E)
Number of subjects: 266
Study 34516998 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportation Incentives (T)
Number of subjects: 266
Study 34516998 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportation & Sessions Incentives (T&S)
Number of subjects: 266
Study 33303468 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated (69 Gy) functional avoidance radiation therapy
Number of subjects: 20
Study 33303468 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional avoidance radiation therapy
Number of subjects: 20
Study 35696071 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax + Azacitidine
Number of subjects: 0
Study 35696071 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine
Number of subjects: 0
Study 32514830 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic instrument group (Group Rob)
Number of subjects: 40
Study 32514830 — intervention group
Group type: COMPARATOR
Intervention: Conventional instrument group (Group Conv)
Number of subjects: 40
Study 32514830 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 32514830 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Rob
Number of subjects: 40
Study 33233510 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosemary extract
Number of subjects: 21
Study 33233510 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 36055304 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for up to 17 cycles
Number of subjects: 994
Study 36055304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 994
Study 36055304 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 994
Study 33270187 — intervention group
Group type: EXPERIMENTAL
Intervention: Equation based on serum β2-microglobulin (β2M), creatinine, urea, age, and gender
Number of subjects: 511
Study 33270187 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (24-h urine collection)
Number of subjects: 511
Study 35346330 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of products with low amounts of PN or TN on a regular basis, starting with 1/100 of their individual threshold, increasing to 1/50 and 1/10 after 4 and 8 months, respectively.
Number of subjects: 120
Study 35346330 — intervention group
Group type: COMPARATOR
Intervention: Strict avoidance of PN or TN for 1 year.
Number of subjects: 120
Study 35346330 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular consumption of PN and/or TN for sensitized but tolerant subjects.
Number of subjects: 120
Study 32892317 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored written advice targeting lifestyle according to current guidelines
Number of subjects: 111
Study 32892317 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 111
Study 32302788 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized clinical decision support (CDS) tool for AF management
Number of subjects: 1145
Study 32302788 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1145
Study 33576204 — intervention group
Group type: EXPERIMENTAL
Intervention: 25mg subcutaneous progesterone (Prolutex, IBSA Switzerland)
Number of subjects: 0
Study 33576204 — intervention group
Group type: COMPARATOR
Intervention: 400mg vaginal progesterone (Cyclogest, Actoverco, United Kingdom)
Number of subjects: 0
Study 32439205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa spray
Number of subjects: 200
Study 35440940 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC combined with NIV (Humidified High Flow Nasal Cannula + Noninvasive Mechanical Ventilation)
Number of subjects: 100
Study 35440940 — intervention group
Group type: COMPARATOR
Intervention: Routine oxygen therapy combined with NIV (low flow conventional oxygen therapy + NIV)
Number of subjects: 100
Study 35440940 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC combined with NIV
Number of subjects: 100
Study 35440940 — intervention group
Group type: COMPARATOR
Intervention: Routine oxygen therapy combined with NIV
Number of subjects: 100
Study 33509257 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified MSFE
Number of subjects: 25
Study 33509257 — intervention group
Group type: COMPARATOR
Intervention: Standard MSFE
Number of subjects: 25
Study 32943231 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% (v/v) DMSO wet‐bonding (DWB)
Number of subjects: 0
Study 32943231 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01%, 0.1%, and 1 wt% EGCG‐incorporated 50% (v/v) DMSO wet‐bonding (0.01%, 0.1%, and 1%EGCG/DWB)
Number of subjects: 0
Study 32943231 — intervention group
Group type: EXPERIMENTAL
Intervention: 1%EGCG/DWB
Number of subjects: 0
Study 32943231 — intervention group
Group type: COMPARATOR
Intervention: water wet‐bonding (WWB)
Number of subjects: 0
Study 36042448 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated Growth Factor (CGF)
Number of subjects: 37
Study 36042448 — intervention group
Group type: COMPARATOR
Intervention: Control (no CGF)
Number of subjects: 37
Study 33983207 — intervention group
Group type: EXPERIMENTAL
Intervention: Random depolarization film (RDF) on display
Number of subjects: 0
Study 33983207 — intervention group
Group type: COMPARATOR
Intervention: Complex polarization-control technologies
Number of subjects: 0
Study 36194310 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pelvic exenteration (LPE)
Number of subjects: 144
Study 36194310 — intervention group
Group type: COMPARATOR
Intervention: Open pelvic exenteration (OPE)
Number of subjects: 144
Study 33472779 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with knowledge of hypertension consequences and treatment options
Number of subjects: 833
Study 33472779 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals who believed BP medications should be stopped from time to time
Number of subjects: 833
Study 33472779 — intervention group
Group type: COMPARATOR
Intervention: Individuals who reported not taking daily treatment
Number of subjects: 833
Study 33472779 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals listing BP medications as the most effective way to reduce BP
Number of subjects: 833
Study 32500209 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-assisted psychotherapy (75-125 mg doses during sessions)
Number of subjects: 0
Study 32833889 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral chest press (CP) training
Number of subjects: 30
Study 32833889 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip training
Number of subjects: 30
Study 32968946 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐PRG filler‐containing coat
Number of subjects: 3
Study 32968946 — intervention group
Group type: EXPERIMENTAL
Intervention: nonS‐PRG filler‐containing coat
Number of subjects: 3
Study 32968946 — intervention group
Group type: COMPARATOR
Intervention: no coating (control)
Number of subjects: 3
Study 32280083 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral omega-3 poly-unsaturated fatty acids (n-3 PUFAs)
Number of subjects: 56
Study 32280083 — intervention group
Group type: COMPARATOR
Intervention: Low calorie diet (LCD)
Number of subjects: 56
Study 32280083 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (omega-3 and LCD)
Number of subjects: 56
Study 36095308 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (up to 400 mg/day)
Number of subjects: 25
Study 36095308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 36095308 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 25
Study 32940857 — intervention group
Group type: EXPERIMENTAL
Intervention: STRONG intervention
Number of subjects: 119
Study 32940857 — intervention group
Group type: COMPARATOR
Intervention: Waitlist comparison group
Number of subjects: 119
Study 32232721 — intervention group
Group type: EXPERIMENTAL
Intervention: Omaha system-based continuing nursing program
Number of subjects: 203
Study 32232721 — intervention group
Group type: COMPARATOR
Intervention: Common outpatient nursing intervention
Number of subjects: 203
Study 35845459 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuina therapy
Number of subjects: 84
Study 35845459 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation control
Number of subjects: 84
Study 33206043 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep hygiene instructions, including instructions to limit liquids at nighttime and empty bladder prior to bedtime
Number of subjects: 0
Study 33206043 — intervention group
Group type: COMPARATOR
Intervention: No sleep instructions (Control)
Number of subjects: 0
Study 33239038 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 120
Study 33239038 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face information, motivation, and behavioral skills model
Number of subjects: 120
Study 33239038 — intervention group
Group type: EXPERIMENTAL
Intervention: Information, motivation, and behavioral skills model provided using a mobile application
Number of subjects: 120
Study 33239038 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 35353333 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 week course of doxycycline, streptomycin, and hydroxychloroquine (DSH)
Number of subjects: 92
Study 35353333 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 week course of doxycycline, streptomycin, and hydroxychloroquine (DSH)
Number of subjects: 92
Study 33677766 — intervention group
Group type: EXPERIMENTAL
Intervention: Connect through PLAY intervention
Number of subjects: 167
Study 33677766 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 167
Study 32497146 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oleic and low-linolenic mutant breeding lines
Number of subjects: 0
Study 32497146 — intervention group
Group type: COMPARATOR
Intervention: High-yielding domestic canola-type breeding lines
Number of subjects: 0
Study 33736862 — intervention group
Group type: EXPERIMENTAL
Intervention: Kois Dento‐Facial Analyzer (KDFA)
Number of subjects: 15
Study 33736862 — intervention group
Group type: EXPERIMENTAL
Intervention: Panadent Pana‐Mount Facebow (PMF)
Number of subjects: 15
Study 33736862 — intervention group
Group type: COMPARATOR
Intervention: Kinematic Axis (KA)
Number of subjects: 15
Study 34270348 — intervention group
Group type: EXPERIMENTAL
Intervention: MIBG (18 mCi/kg on day 1)
Number of subjects: 105
Study 34270348 — intervention group
Group type: EXPERIMENTAL
Intervention: MIBG + Vincristine (IV on day 0) + Irinotecan (daily on days 0-4)
Number of subjects: 105
Study 34270348 — intervention group
Group type: EXPERIMENTAL
Intervention: MIBG + Vorinostat (180 mg/m2/dose orally once daily on days 1 to 12)
Number of subjects: 105
Study 34270348 — intervention group
Group type: COMPARATOR
Intervention: MIBG
Number of subjects: 105
Study 34270348 — intervention group
Group type: COMPARATOR
Intervention: MIBG + Vincristine + Irinotecan
Number of subjects: 105
Study 34270348 — intervention group
Group type: COMPARATOR
Intervention: MIBG + Vorinostat
Number of subjects: 105
Study 32690001 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT) - single dose (wavelength 830nm, energy 2J/point) applied at four points (2 buccal, 2 palatal) for each maxillary anterior tooth root.
Number of subjects: 26
Study 32690001 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment - same application procedure without emitting the laser beam.
Number of subjects: 26
Study 35422183 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyphosate low dose of 7.2 g a.e. ha‐1
Number of subjects: 0
Study 35422183 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyphosate low dose of 36.0 g a.e. ha‐1
Number of subjects: 0
Study 35422183 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyphosate low dose of 108.0 g a.e. ha‐1
Number of subjects: 0
Study 33676014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling for 30 minutes
Number of subjects: 20
Study 33676014 — intervention group
Group type: EXPERIMENTAL
Intervention: Running for 30 minutes
Number of subjects: 20
Study 33676014 — intervention group
Group type: COMPARATOR
Intervention: Resting
Number of subjects: 20
Study 34592023 — intervention group
Group type: EXPERIMENTAL
Intervention: BES-SMFR
Number of subjects: 68
Study 34592023 — intervention group
Group type: COMPARATOR
Intervention: BES
Number of subjects: 68
Study 33812261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy (ozonated water at 25 µg/mL concentration and ozone gas)
Number of subjects: 60
Study 33812261 — intervention group
Group type: COMPARATOR
Intervention: Control (saline irrigation)
Number of subjects: 60
Study 33167759 — intervention group
Group type: EXPERIMENTAL
Intervention: Intular Scope™ (IS)
Number of subjects: 70
Study 33167759 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscope (DL)
Number of subjects: 70
Study 36414261 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation (one session applied to anterior chamber nodules)
Number of subjects: 48
Study 36414261 — intervention group
Group type: COMPARATOR
Intervention: Topical steroid and cycloplegic eye drops with trans-septal triamcinolone injections
Number of subjects: 48
Study 33113053 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-field organ dose modulation (ODM)
Number of subjects: 80
Study 33113053 — intervention group
Group type: COMPARATOR
Intervention: Regular scanning patterns
Number of subjects: 80
Study 32727938 — intervention group
Group type: EXPERIMENTAL
Intervention: Test TCV
Number of subjects: 240
Study 32727938 — intervention group
Group type: COMPARATOR
Intervention: Comparator TCV
Number of subjects: 240
Study 32727938 — intervention group
Group type: EXPERIMENTAL
Intervention: Test TCV and Comparator TCV
Number of subjects: 240
Study 34435252 — intervention group
Group type: EXPERIMENTAL
Intervention: GT (Rebilda bundled glass fiber-reinforced composite posts)
Number of subjects: 80
Study 34435252 — intervention group
Group type: EXPERIMENTAL
Intervention: RP (Rebilda conventional glass fiber posts)
Number of subjects: 80
Study 34435252 — intervention group
Group type: EXPERIMENTAL
Intervention: GT + RP (combined intervention)
Number of subjects: 80
Study 34435252 — intervention group
Group type: COMPARATOR
Intervention: Control groups (nWnR, WnR, nWGT, WGT, nWRP, WRP)
Number of subjects: 80
Study 34231948 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat platform management
Number of subjects: 566
Study 34231948 — intervention group
Group type: COMPARATOR
Intervention: Traditional management method (Control)
Number of subjects: 566
Study 32171945 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated WBI
Number of subjects: 140
Study 32171945 — intervention group
Group type: COMPARATOR
Intervention: Conventional WBI
Number of subjects: 140